|
WO2015006833A1
|
|
A method for treating type 1 diabetes
|
|
EP2331135A1
|
|
Methods of treating and preventing glucose toxicity
|
|
WO2008052277A1
|
|
Crystalline composition of gm-csf/gm-csfr
|
|
US2003228592A1
|
|
Human facilitative glucose transport protein GLUT8
|
|
AU2002357407A1
|
|
Amp kinase beta-subunit oligosaccharide binding domain
|
|
WO03056032A1
|
|
Amp kinase beta-subunit oligosaccharide binding domain
|
|
AU2002952817A0
|
|
Method for the detection of newly acquired hiv infection
|
|
AUPS189802A0
|
|
Tumour cell
|
|
AUPR818801A0
|
|
Methods for identifying and treating metastatic disease
|
|
AU5797500A
|
|
Inhibitor of osteoclast precursor formation
|
|
AUPQ167599A0
|
|
Inhibitor of osteoclast precursor formation
|
|
AUPP899699A0
|
|
Peptides, agents and methods
|
|
AUPP857699A0
|
|
Cytokine-binding domain
|
|
AUPP855699A0
|
|
Viral transmembrane protein structure
|
|
AUPP697698A0
|
|
Regulation of enzyme activity
|
|
AU9331398A
|
|
Human facilitative glucose transport protein glut8
|
|
AUPO957397A0
|
|
Transporter protein
|
|
AU2145497A
|
|
Immunological rejection of transfected tumour cells
|
|
AUPN912396A0
|
|
Complement mediated rejection of transfected tumour cells
|
|
AUPN745096A0
|
|
Novel amp activated protein kinase
|
